ClinicalTrials.gg
CompletedNCT04252495Updated Nov 23, 2022

The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

A Phase 1 interventional study of Aprocitentan in Hepatic Impairment and Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 2 sites in 2 countries. Open to participants aged 30 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
30 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Liver Diseases with a site in Germany — 10 open to participants now, 13 under way, 5 of them phase 3. Liver Diseases · Germany.

Enrollment
41st of 44
17 · median 128
Started
2020
with 1 other
Phase 1
9 of 54
1 open now
Registered
32nd of 54
by date

Among the 54 studies in Liver Diseases with a site in Germany, this one is the 41st largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2020, is one of 9 in phase 1, and was the 32nd registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

10 of the 54 studies in Liver Diseases with a site in Germany are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 30 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Liver Diseases with a site in Germany, or all of them as a file.
02

Study summary

This is a prospective, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

03

Conditions studied

  • Hepatic Impairment
  • Healthy Subjects

Browse trials for

Keywords

  • Liver Diseases
04

Who can participate

Ages eligible
30 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure.
  • Women of (WoCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1 and must agree to use highly effective methods of from screening up to 30 days after study treatment.
  • A Women of non-childbearing potential (WoNCBP) must meet one of the following criteria:

    • Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy.
    • Premature ovarian failure confirmed by a specialist gynecologist.
    • , defined as 12 consecutive months with amenorrhea prior to screening without alternative medical cause and confirmed with a follicle stimulating hormone test.
  • of 18.0 to 35.0 kg/m2 (inclusive) at screening.
  • Normal renal function confirmed by a at screening according to Cockcroft and Gault adjusted to age.
  • Additional principal inclusion criteria for subjects with moderate hepatic impairment (Group 1)

    • Moderate hepatic function impairment due to liver cirrhosis defined as a score of 7-9 (inclusive) according to the classification.
    • Systolic blood pressure 95 to 160 mmHg, diastolic blood pressure 60 to 95 mmHg, and pulse rate 50 to 100 bpm (inclusive), measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 pre-dose.
    • equal or less than 2.5 at screening.
    • Stable concomitant medications for at least 3 weeks prior to screening and up to Day 1 and expected to be stable during the conduct of the study.
  • Additional principal inclusion criteria for healthy subjects (Group 2)

    • Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • Previous exposure to aprocitentan and/or macitentan.
  • Known to any of the drug formulation.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Any signs or symptoms of active, ongoing infection judged to be by the investigator (special attention should be given to COVID-19, e.g., fever, dry cough, dyspnea, sore throat, or fatigue).
  • Subjects must adhere to the clinical site's house rules, which include, amongst others, polymerase chain reaction testing for SARS-CoV-2 at screening and admission.
  • Legal incapacity or limited legal capacity at screening.
  • Additional exclusion criteria for subjects with moderate hepatic impairment (Group 1)

    • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion (ADME) of the study treatment except for those related to liver cirrhosis (appendectomy and herniotomy allowed, cholecystectomy not allowed).
    • Hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease.
    • Clinical evidence or suspected acute liver failure as judged by the investigator.
    • Encephalopathy grade greater than 2.
    • Severe ascites and/or pleural effusion.
    • Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening \& on Day -1, except for those related to liver cirrhosis.
  • Additional exclusion criteria for healthy subjects (Group 2)

    • Clinically relevant findings on the physical examination at screening.
    • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion (ADME) of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
    • Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening \& on Day -1.
    • Clinically relevant abnormalities on a 12-lead , recorded after 5 min in the supine position at screening \& on Day 1 pre-dose.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Subjects with moderate hepatic impairment (Group 1)

    Drug: Aprocitentan

  • Experimental
    Healthy subjects (Group 2)

    Drug: Aprocitentan

Interventions

  • A single oral dose of 25 mg.

    Also known as: ACT-132577

06

What researchers measure

Primary outcomes

  1. The maximum plasma concentration (Cmax) of aprocitentan

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.

  2. Area under the plasma concentration-time curves (AUC0-t) of aprocitentan

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.

  3. Area under the plasma concentration-time curve to infinity (AUC0 to inf) of aprocitentan

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.

Secondary outcomes

  1. Treatment-emergent Adverse Events

    Time frame: From study treatment administration on Day 1 up to last assessment on End of Study (Day 15)

07

Study locations

2 sites
  • CRS Clinical Research Services Kiel GmbH
    Kiel, 24105, Germany
  • Biokinetica S.A.
    Jozefow, 05-410, Poland
08

References and documents

Publications

  • Fontes MSC, Dingemanse J, Halabi A, Tomaszewska-Kiecana M, Sidharta PN. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Sci Rep. 2022 Nov 9;12(1):19067. doi: 10.1038/s41598-022-22470-z. PubMed 36352054 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Apr 2021, 9 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2020
First posted
Feb 5, 2020
StartActual
Jun 26, 2020
Primary completionActual
Apr 5, 2021
CompletionActual
May 6, 2021
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04252495
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Jun 26, 2020
Primary completion
Apr 5, 2021
Completion
May 6, 2021
Last update
Nov 23, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion